Neurogen: Phase 2 trial results are positive for insomnia drug candidate

By E. Janene Geiss

Philadelphia, May 11 - Neurogen Corp. announced Thursday top-line results of phase 2 human testing in transient insomnia for the company's internally discovered drug candidate for insomnia, NG2-73.

The primary endpoint of the study measured the efficacy of NG2-73 in reducing time to onset of persistent sleep in a well-established clinical model of transient insomnia in healthy adults, according to a company news release.

In this multi-center, 369-subject study, NG2-73 was shown to significantly reduce time to onset of persistent sleep versus placebo at all doses tested, officials said.

In top-line results, NG2-73 demonstrated statistically significant improvement over placebo for reducing Latency to Persistent Sleep at all doses tested.

NG2-73 was well-tolerated at all doses with no drug-related serious adverse events or drug-related premature subject withdrawals, officials said.

"The fast onset of action of this compound may serve to differentiate it from other sleep agents," Gary Zammit, president and chief executive officer of CliniLabs, Inc. and clinical associate professor of psychology at Columbia University College of Physicians and Surgeons, said in the release.

NG2-73 is a partial agonist, preferential for the alpha-3 receptor subtype of the gamma-aminobutyric acid neurotransmitter system.

Neurogen is a Branford, Conn., drug discovery and development company focusing on small molecule drugs to treat insomnia, pain, depression, obesity and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.